editedbook
Publication: IIP Proceedings Year: 2022, Month: November Page No: 210-228, ISSN/ISBN: 978-93-95632-86-7 0, DOI/Link: https://rsquarel.org/assets/docupload/rsl2023514BEA8D0419629.pdf
BIOMARKERS
Area/Stream: Pharmacy & Nursing, Authors: Yashomita Mehta, Rupali Sharma, Jagriti Narang, Shekhar Sharma, Suman Khurana Keywords: Biomakres Book Name /series: Futuristic Trends in Pharmacy & Nursing,Volume 2, Book 23, Chapter 17Publication: IIP Proceedings Year: 2022, Month: November Page No: 210-228, ISSN/ISBN: 978-93-95632-86-7 0, DOI/Link: https://rsquarel.org/assets/docupload/rsl2023514BEA8D0419629.pdf
Abstract:
A biomarker is a biological finding that, in theory, predicts and serves as a stand-in for a clinically significant endpoint or intermediate outcome that is more challenging to observe. Because biomarkers are used so often in scientific and clinical research, as well as in clinical practise, it is now nearly universally acknowledged that they should be used as primary endpoints in clinical studies. This use is totally legitimate and suitable in the case of certain biomarkers that have been thoroughly defined and consistently demonstrated to accurately predict pertinent clinical outcomes across a range of treatments and demographics. However, the "validity" of biomarkers is frequently presumed when it should be tested and retested. To provide context for interpreting studies that extensively rely on such biological measures, this article will examine the current conceptual position of biomarkers as clinical and diagnostic tools and as surrogate endpoints in clinical research. [1] Clinical biomarkers are typically assessed over a shorter time than the final clinical objective, making their application simpler and less expensive. They can be utilised for pharmacodynamic and dose-response investigations as well as for illness screening, diagnosis, characterisation, and monitoring as prognostic markers for developing tailored therapeutic interventions for predicting and treating adverse drug responses. Good biomarkers should have a large signal-to-noise ratio, be quantifiable with little to no fluctuation, and change quickly and consistently in response to changes in the condition or its treatment. Biomarkers are the cornerstone of a precision approach to clinical medicine and have the potential to dramatically improve and speed up the development of new therapeutics for patients with a variety of diseases such as tumours, heart problems, etc.
Cite this: Yashomita Mehta, Rupali Sharma, Jagriti Narang, Shekhar Sharma, Suman Khurana,"BIOMARKERS", Futuristic Trends in Pharmacy & Nursing,Volume 2, Book 23, Chapter 17, November, 2022, 210-228, 978-93-95632-86-7 0, https://rsquarel.org/assets/docupload/rsl2023514BEA8D0419629.pdf
Views: 4176
Download File
News